
Extracted Table from Page 11:
['No.', 'PARAMETERS', 'COMPONENTS', 'REQUIREMENTS', None, None, None, None]
[None, None, None, 'NCE', 'BIOTECH', 'MaV', 'MiV', 'G']

Extracted Table Text from Page:
This document is intended to provide guidance on the format of a registration 
application for drug products regarding ASEAN CTR. This format is 
appropriate for NCE (New Chemical Entity), Biotech (Biotechnological 
Products), MaV (Major Variations), MiV (Minor Variations) and G (Generics). 
To determine the applicability of this format for a particular type of product, 
applicant should consult with the appropriate National Regulatory 
Authorities. The “Body of Data” in this guideline merely indicates where 
the information should be located. Neither the type nor extent of specific 
supporting data has been addressed in this guideline and both may depend 
upon national guidance and or accepted leading international references 
(pharmacopoeias).
For NCE and Biotech requirements please refer to the relevant ICH 
Guidelines.
Section A: Table of Contents
A table of contents for the filed application should be provided.
Section b: Quality Overall Summary (QOS)
No.
PARAMETERS
COMPONENTS
REQUIREMENTS
NCE
BIOTECH
MaV
MiV
G
S
DRUG SUBSTANCE
S1
General Information


--------------------------------------------------

Extracted Table from Page 12:
['No.', 'PARAMETERS', 'COMPONENTS', 'REQUIREMENTS', None, None, None, None]
[None, None, None, 'NCE', 'BIOTECH', 'MaV', 'MiV', 'G']

Extracted Table Text from Page:
No.
PARAMETERS
COMPONENTS
REQUIREMENTS
NCE
BIOTECH
MaV
MiV
G
S2
Manufacture
2.1. Manufacturer(s)
Name and address of the manufacturer (s).



2.2. Description of 
− The description of the drug substance 




--------------------------------------------------

Extracted Table from Page 13:
['No.', 'PARAMETERS', 'COMPONENTS', 'REQUIREMENTS', None, None, None, None]
[None, None, None, 'NCE', 'BIOTECH', 'MaV', 'MiV', 'G']

Extracted Table Text from Page:
No.
PARAMETERS
COMPONENTS
REQUIREMENTS
NCE
BIOTECH
MaV
MiV
G
− Details on primary, secondary and 
higher- order structure  and information 
on biological activity,  purity  and 
immunochemical
properties
(when



--------------------------------------------------

Extracted Table from Page 14:
['No.', 'PARAMETERS', 'COMPONENTS', 'REQUIREMENTS', None, None, None, None]
[None, None, None, 'NCE', 'BIOTECH', 'MaV', 'MiV', 'G']

Extracted Table Text from Page:
No.
PARAMETERS
COMPONENTS
REQUIREMENTS
NCE
BIOTECH
MaV
MiV
G
P2
Pharmaceutical Development
2.1 Information on 
Development Studies
−  Data on the development  studies 
conducted to establish that the dosage 
form, 
formulation, 
manufacturing 
process, container closure system, 
microbiological attributes and usage 
instruction are appropriate for the 
purpose specified in the application.


2.2. Components of the Drug 
Product
− Active ingredient
• Justification of the compatibility of the 
active ingredient with excipients listed 
in P1


• In  case  of  combination products, 
justification of the compatibility of 
active ingredients with each other.
− Literature data.
*

−  Excipients


 Justification of the choice of excipients 
listed in P1, which may influence the 
drug product performance.
2.3. Finished Product
−  Formulation Development



 A 
brief 
summary 
describing 
the 
development of the finished product, 
(taking into consideration the proposed 
route of administration and usage for 
NCE and Biotech).
−  Overages



 Justification of any overage in the 
formulation(s) described in P1 .


--------------------------------------------------

Extracted Table from Page 15:
['No.', 'PARAMETERS', 'COMPONENTS', 'REQUIREMENTS', None, None, None, None]
[None, None, None, 'NCE', 'BIOTECH', 'MaV', 'MiV', 'G']

Extracted Table Text from Page:
No.
PARAMETERS
COMPONENTS
REQUIREMENTS
NCE
BIOTECH
MaV
MiV
G
P3
Manufacture
3.1. Batch Formula
Name and quantities of all ingredients


*

3 2 Manufacturing Process
Description
of
manufacturing
process


*
*



--------------------------------------------------

Extracted Table from Page 16:
['No.', 'PARAMETERS', 'COMPONENTS', 'REQUIREMENTS', None, None, None, None]
[None, None, None, 'NCE', 'BIOTECH', 'MaV', 'MiV', 'G']
['P6\nP7\nP8\nP9', 'Reference Standards or\nMaterials\nContainer Closure System\nStability\nProduct Interchangeability\nEquivalence evidence', '− Information on the reference standards\nor reference materials used for testing of\nthe finished product.\nCompendial requirements or appropriate\ninformation from the manufacturer\n− Specification and control of primary and\nsecondary packaging material, type of\npackaging and the package size, details\nof packaging inclusion (e.g. desiccant,\netc)\nStability report: data demonstrating that\nproduct is stable through its proposed\nshelf life.\nCommitment on post approval stability\nmonitoring\n− In Vitro\nComparative dissolution study as\nrequired\n− In Vivo\nBioequivalence study as required', '\uf0fc\n\uf0fc\n\uf0fc', '\uf0fc\n\uf0fc\n\uf0fc', '\uf0fc*\n\uf0fc*\n\uf0fc*\n\uf0fc*\n\uf0fc*', '\uf0fc*', '\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc']

Extracted Table Text from Page:
No.
PARAMETERS
COMPONENTS
REQUIREMENTS
NCE
BIOTECH
MaV
MiV
G
P6
Reference Standards or 
Materials
−  Information on the reference standards 
or reference materials used for testing of 
the finished product.


 Compendial requirements or appropriate 
information from the manufacturer
*

P7
Container Closure System
− Specification and control of primary and 
secondary packaging  material, type of 
packaging and the package size, details 
of packaging inclusion (e.g. desiccant, 
etc)


*
*

P8
Stability
 Stability report: data demonstrating that 
product is stable through its proposed 
shelf life.


*

 Commitment on post approval stability 
monitoring
P9
Product Interchangeability 
Equivalence evidence
− In Vitro
*

 Comparative 
dissolution 
study 
as 
required
− In Vivo
*

 Bioequivalence study as required
remarks : * if required
 
 NCE 
: 
New Chemical Entity
 
 Biotech 
: 
Biotechnological Products
 
 MaV 
: 
Major Variation
 
 MiV 
: 
Minor Variation
 
 G 
: 
Generics


--------------------------------------------------

Extracted Table from Page 55:
['Study type and\nduration', 'Route of\nadministration', 'Species', 'Compound\nadministered*']
['Single-dose toxicity', 'Po and iv', 'Rat and mouse', 'Parent drug']
['Single-dose toxicity', 'Po and iv', 'Rat and mouse', 'Metabolite X']
['Repeat-dose toxicity', '', '', '']
['1 month', 'po', 'Rat and dog', 'Parent drug']
['6 month', 'po', 'Rat', 'Parent drug']
['9 month', 'po', 'Dog', 'Parent drug']

Extracted Table Text from Page:
y Program
e and 
on
Route of 
administration
Species
C
ad
toxicity
Po and iv
Rat and mouse
Par
toxicity
Po and iv
Rat and mouse
Met
e toxicity
po
Rat and dog
Par
po
Rat
Par
po
Dog
Par
should be included only if metabolites are investiga
of the toxicologic evaluation should be d


--------------------------------------------------

Extracted Table from Page 109:
['Part III: Document', 'NCE', 'BIOTECH', 'MaV', None, None, 'MiV', 'G']
[None, None, None, 'RT', 'S/P', 'IND', '', '']
['Section A. Table of Content', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '', '']
['Section B. Nonclinical Overview', '\uf0fc', '\uf0fc', '', '', '', '', '']
['1. General Aspect\n2. Content and structural format', '\uf0fc', '\uf0fc', '', '', '', '', '']
['Section C. Nonclinical Summary (Written and\nTabulated)', '\uf0fc', '\uf0fc', '', '', '', '', '']
['1. Nonclinical Written Summaries', '', '', '', '', '', '', '']
['1.1 Pharmacology\n1.1.1 Primary Pharmacodynamics\n1.1.2 Secondary Pharmacodynamics\n1.1.3 Safety Pharmacology\n1.1.4 Pharmcodynamics Drug Interactions', '\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc', '\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc', '', '', '', '', '']
['1.2 Pharmacokinetics\n1.2.1 Absorption\n1.2.2 Distribution\n1.2.3 Metabolism\n1.2.4 Excretion\n1.2.5 Pharmacokinetics Drug Interaction\n(non- clinical)\n1.2.6 Other Pharmacokinetics Studies', '\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc', '\uf076\n\uf076\n\uf076\n\uf076', '\uf076\n\uf076\n\uf076\n\uf076\n\uf076', '\uf076\n\uf076\n\uf076\n\uf076', '', '', '']

Extracted Table Text from Page:
Interactions




Interaction 
Studies





















--------------------------------------------------

Extracted Table from Page 110:
['Part III: Document', 'NCE', 'BIOTECH', 'MaV', None, None, 'MiV', 'G']
[None, None, None, 'RT', 'S/P', 'IND', '', '']
['1.3 Toxicology\n1.3.1 Single dose toxicity\n1.3.2 Repeat dose toxicity\n1.3.3 Genotoxicity\n1.3.4 Carcinogenicity\n1.3.5 Reproductive and developmental\ntoxicity\n1.3.5.1 Fertility and early embryonic\ndevelopment\n1.3.5.2 Embryo-fetal development\n1.3.5.3 Prenatal and postnatal\ndevelopment\n1.3.6 Local tolerance\n1.3.7 Other toxicity studies, if available', '\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf076\n\uf076', '\uf0fc\n\uf0fc\n\uf074\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf076\n\uf076', '\uf076\n\uf076', '\uf076\n\uf076', '\uf076\n\uf076', '', '']
['2. Nonclinical Tabulated Summaries', '\uf0fc', '\uf0fc', '\uf076', '\uf076', '\uf076', '', '']
['Section D. Nonclinical Study Report (As requested)', '', '', '', '', '', '', '']
['1. Table of Content', '\uf0fc', '\uf0fc', '', '', '', '', '']
['2. Pharmacology\n2.1 Primary Pharmacodynamics\n2.2 Secondary Pharmacodynamics\n2.3 Safety Pharmacology\n2.4 Pharmacodynamics Drug Interactions', '\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc', '\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc', '', '', '', '', '']

Extracted Table Text from Page:
 available










As requested)


cs
ractions










--------------------------------------------------

Extracted Table from Page 111:
['Part III: Document', 'NCE', 'BIOTECH', 'MaV', None, None, 'MiV', 'G']
[None, None, None, 'RT', 'S/P', 'IND', '', '']
['3. Pharmacokinetics\n3.1 Analytical Methods and Validation Reports\n3.2 Absorption\n3.3 Distribution\n3.4 Metabolism\n3.5 Excretion\n3.6 Pharmacokinetics Drug Interaction (non-\nclinical)\n3.7 Other Pharmacokinetics studies', '\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc', '\uf076\n\uf076\n\uf076\n\uf076\n\uf076\n\uf076\n\uf076', '\uf076\n\uf076\n\uf076\n\uf076\n\uf076', '\uf076\n\uf076\n\uf076\n\uf076', '', '', '']
['4. Toxicology\n4.1 Single dose toxicity\n4.2 Repeat dose toxicity\n4.3 Genotoxicity\n4.3.1 In vitro\n4.3.2 In vivo\n4.4 Carcinogenicity\n4.4.1 Long term studies\n4.4.2 Short or medium term studies\n4.4.3 Other studies\n4.5 Reproductive and developmental toxicity\n4.5.1 Fertility and early embryonic\ndevelopment\n4.5.2 Embryo-fetal development\n4.5.3 Prenatal and postnatal development\n4.5.4 Studies in which the offspring are\ndosed and/or further evaluated', '\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc', '\uf0fc\n\uf0fc\n\uf074\n\uf074\n\uf074\n\uf074\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc\n\uf0fc', '', '', '', '', '']

Extracted Table Text from Page:


--------------------------------------------------

Extracted Table from Page 112:
['Part III: Document', 'NCE', 'BIOTECH', 'MaV', None, None, 'MiV', 'G']
[None, None, None, 'RT', 'S/P', 'IND', '', '']
['4.6 Local tolerance\n4.7 Other toxicity studies, if available\n4.7.1 Antigenicity\n4.7.2 Immunotoxicity\n4.7.3 Dependence\n4.7.4 Metabolites\n4.7.5 Impurities\n4.7.6 Other', '\uf076\n\uf076', '\uf076\n\uf076', '\uf076\n\uf076', '\uf076\n\uf076', '\uf076\n\uf076', '', '']
['Section E. List of Key Literature References', '\uf0fc', '\uf0fc', '\uf076', '\uf076', '\uf076', '', '']

Extracted Table Text from Page:
NCE
BIOTECH
MaV
MiV
G
RT
S/P
IND










s





product that has undergone variation affecting one or more of the following: the route 
posology, indications. The submission of additional data is required and necessary to 
efficacy of the new formulation resulting from the variation)
   -      Strength and Posology IND  -      Indication
l product that has undergone variation affecting one or more of the following: route of 
ology, indications or active ingredient/s. The submission of additional data is required 
uality of the new formulation resulting from the variation)
 route of administration due to change in formulation
echnology-derived products, however, product-specific assessment of carcinogenic 
ding upon duration of clinical dosing, patient population and /or biological activity of the 
munosuppressive agents, etc


--------------------------------------------------

Extracted Table from Page 159:
['Study\nRef. No.', 'Study Objective', 'Study Design', 'Treatments\n(Dose,\nDosage Form,\nRoute) [Product\nID]', 'Subjects\n(No.(M/F)\ntype\nAge: mean\n(range)', 'Mean Parameters (+/- SD)', None, None, None, None, None, 'Study\nReport\nLocation']
['', '', '', '', '', 'Cmax\n(mg/L)', 'Tmax\n(hr)', 'AUC*\n(mg/Lxhr)', 'Cmin**\n(mg/L)', 'T1/2\n(hr)', 'Other', '']
['192\n(Japan)', 'Pilot relative BA\nstudy comparing\nthe absorption\nfrom a 200mg\ntablet batch to a\n200mg reference\nbatch.', 'Open,\nrandomized,\ncross-over,\nsingle 200 mg\ndose', '200mg Tab., p.o.\n[17762]\n200mg Tab.. p.o.\n[19426]', '20 (10/10)\nHealthy\nvolunteer\n27 y (20-35)', '83 ± 21\n80 ± 32', '1\n0.5', '217 ± 20\n223 ± 19', '', '3.1\n2.9', '', '']
['195\n(Japan)', 'Comparative BA\nstudy of xx\nunder fasted and\nfed conditions', 'Open,\nrandomized,\ncross-over,\nsingle dose', '200mg Tab, p.o.\n[19426]', '30 (15/15)\nHealthy\nvolunteer\n32 y (26-50)', '83 ± 21\n120 ± 30', '1\n2', '217 ± 20\n350 ± 40', '', '', '', '']

Extracted Table Text from Page:


--------------------------------------------------

Extracted Table from Page 160:
['Study\nRef.\nNo.', 'Product\nID/Batch No.', 'Dosage Form', 'Conditions', 'No. of\nDosage\nUnits', 'Collection times\nMean % Dissolved (range)', 'Study\nReport\nLocation']
['1821', '979-03', '25mg Cap.', 'Dissolution: Apparatus 2 (USP)\nSpeed of Rotation: 50 rpm\nMedium/Temperature: Water 37°', '12', '10 20 30 (min)\n42 (32-49) 71 (58-85) 99 (96-100) (%)', '']
['', '', '', '', '', '', '']
['', '', '', '', '', '', '']
['', '', '', '', '', '', '']
['', '', '', '', '', '', '']

Extracted Table Text from Page:
Study 
Report 
Location
(min)
0) (%)


--------------------------------------------------

Extracted Table from Page 161:
['Study/\nProtocol #\n(Country)', 'Product\nID/Batch\n# (NME)', 'Study\nObjective', 'Study\nDesign', '# Subjects\nEntered/\nComplet\ned (M/F)', 'HV/P1\n(Age:\nMean,\nrange)', 'Treatments', None, 'Mean Pharmacokinetic Parameters (%CV)\nSubstrate Drug', None, None, None, None, 'Mean ratio2\nConfidence\ninterval', None, 'Location']
['', '', '', '', '', '', 'Substrate', 'Interacting\nDrug', 'Cmax', 'Tmax', 'AUC', 'T1/2', 'CL/kg', 'Cmax', 'AUC', '']
['001\n(USA)', '19B\nBatch\n0034', 'Effect of\nwarfarin on\nDrug X', 'Randomi\nzed,\nCross\nover', '(8M/4F)/\n(7M/4F)', 'HV (34,\n20-41)', 'Drug X 100\nmg bid x 7d', 'Placebo', '45 (18)\nΦg/mL', '2.0\n(30) hr', '456 (24)\nΦg*hr/\nmL', '4.25\n(30)\nhr', '0.05 (20)\nmL/\nmin/k g', '1.16\n1.01-\n1.30', '1.16\n1.03-\n1.34', '']
['', '', '', '', '', '', 'Drug X 100\nmg bid x 7d', 'Warfarin 10\nmg qd x 7d', '52 (20)\nΦg/mL', '2.1\n(35) hr', '530 (27)\nΦg*hr/\nmL', '4.75\n(35)\nhr', '0.04 (22)\nmL/\nmin/k g', '', '', '']
['001\n(USA)', '19B\nBatch\n0034', 'Effect of\ndrug X on\nwarfarin', 'Randomi\nzed,\nCross\nover', '(8M/4F)/\n(7M/4F)', 'HV (34,\n20-41)', 'Warfarin 10\nmg qd x 7d', 'Placebo', '12 (25)\nΦg/mL', '1.5\n(30) hr', '60 (37)\nΦg*hr/\nmL', '40\n(35)\nhr', '0.04 (30)\nmL/\nmin/k g', '1.08\n0.92-\n1.24', '1.07\n0.92-\n1.18', '']
['', '', '', '', '', '', 'Warfarin 10\nmg qd x 7d', 'Drug X 100\nmg bid x 7d', '13 (20)\nΦg/mL', '1.45\n(27) hr', '64 (39)\nΦg*hr/\nmL', '42\n(37)\nhr', '0.39 (34)\nmL/\nmin/k g', '', '', '']
['002 (UK)', '19B2\nBatch\n0035', 'Effect of\nCimetidine\non Drug X', 'Cross\nover,\nSingle\nsequence', '(4M/8F)\n(4M/8F)', 'HV (30,\n19-45)', 'Drug X 50\nmg\nbid x 5d', 'Placebo', '49 (18)\nΦ/mL', '2.1\n(30) hr', '470 (24)\nΦg*hr/\nmL', '4.4\n(30)\nhr', '0.05 (20)\nmL/\nmin/k g', '1.22\n1.03-\n1.40', '1.36\n1.11-\n1.53', '']
['', '', '', '', '', '', 'Drug X 50\nmg\nbid x 5d', 'Cimetidine\n200 mg bid\nx 5d', '60 (10)\nΦg/mL', '2.2\n(30) hr', '640 (24)\nΦg*hr/\nmL', '5.2\n(30)\nhr', '0.03 (20)\nmL/\nmin/k g', '', '', '']

Extracted Table Text from Page:
g
(
)
g
mL
(
)
hr
min/k g
ebo
49 (18)
Φ/mL
2.1
(30) hr
470 (24)
Φg*hr/
mL
4.4
(30)
hr
0.05 (20)
mL/
min/k g
1.22
1.03-
1.40
1.36
1.11-
1.53
etidine
mg bid 
60 (10)
Φg/mL
2.2
(30) hr
640 (24)
Φg*hr/
mL
5.2
(30)
hr
0.03 (20)
mL/
min/k g


--------------------------------------------------

Extracted Table from Page 162:
['Study\nID', 'Number\nof Study\nCenters\nLocation\n(s)', 'Study start\nEnrollment\nstatus, date\nTotal\nenrollment\n/ Enrollment\ngoal', 'Design\nControl type', 'Study & Ctrl\nDrugs\nDose, Route\n& Regimen', 'Study\nObjective', '# subjs\nby arm\nEntere d/\ncompl.', 'Duration', 'Gender\nM/F\nMedian Age\n(Range)', 'Diagnosis\nInclusion\nCriteria', 'Primary Endpoint(s)']
['PG- 2476', '1\nU. Antarctica', 'Aug-94\nCompleted\nApr 98\n50 / 50', 'Randomised,\ndouble blind,\nparallel\nPlacebo', 'TP: 30 mg\npo bid\nPbo', 'Efficacy and\nSafety', '27/24\n23/21', '4 weeks', '27/23\n38 (20-64)', 'Mild hypertension\nDiastolic 90-100\nSystolic 150-170', 'Change from baseline\nsystolic and diastolic\npressure at 4 weeks.']
['PG- 2666', '4\nAffiliated\nPhysicians of\nFlorida,\nSmith &\nJones CRO', 'May-98\nOngoing as\nof May\n2001\n126/400', 'Randomised,\nopen label,\nparallel\nPlacebo\nand Dose-\nresponse', 'TP: 100 mg\npo bid\nTP: 50 mg\npo bid\nTP: 25 mg\npo bid\nPlacebo', 'Efficacy and\nSafety,\nLong- term\nefficacy and\nsafety', '34/30\n30/28\n34/32\n28/26', '4 weeks,\nfollowed by\n12 weeks\nopen-label', '66/60\n55 (24-68)', 'Mild hypertension\nSystolic 150-170\nDiastolic 90-100', 'Change from baseline\nsystolic and diastolic\npressure at 4 weeks\nand at 12 weeks.']

Extracted Table Text from Page:


--------------------------------------------------

Extracted Table from Page 163:
['Study', 'Treatment Arm', '# Enrolled/\nCompleted', 'Mean systolic and diastolic\nBP', None, None, 'Primary Endpoint\nPlacebo-subtracted\nchange in DBP at\n40 weeks', 'Statistical\ntest /\nP value', 'Secondary\nEndpoints\n% normalised**\n(ITT analysis)', 'Other\nComments']
[None, None, None, 'Baseline', '20 wks', '40 wks', None, None, None, None]
['PG-\n2678', 'TP: 100 mg po bid\nTP: 50 mg po bid\nTP: 25 mg po bid\nTP: 10 mg po bid\nPlacebo', '34/30\n30/28\n34/32\n26/20\n28/26', '162/96\n165/97\n167/96\n162/95\n166/97', '140/85\n146/87\n148/88\n153/93\n160/92', '138/84\n146/87\n148/88\n153/93\n159/91', '6\n4\n2\n-4', '', '88\n78\n50\n20\n30', '']

Extracted Table Text from Page:
condary
dpoints
rmalised** 
analysis)
Other
Comments
88
78
50
20
30


--------------------------------------------------

Extracted Table from Page 164:
['Duration\n(Weeks)', 'Mean Daily Dose (mg)', None, None, None, None, None, None, None]
[None, '0 < Dose\n≤ 5mg', '5 < Dose\n≤ 10mg', '10 < Dose\n≤ 20mg', '20 < Dose\n≤ 30mg', '30 < Dose\n≤ 50mg', '50mg < Dose', 'Total\n(Any Dose)', 'Percent']
['0 < Dur ≤ 1', '', '', '', '', '', '', '', '']
['1 < Dur ≤ 2', '', '', '', '', '', '', '', '']
['2 < Dur ≤ 4', '', '', '', '', '', '', '', '']
['4 < Dur ≤ 12', '', '', '', '', '', '', '', '']
['12 < Dur ≤ 24', '', '', '', '', '', '', '', '']
['24 < Dur ≤ 48', '', '', '', '', '', '', '', '']
['48 < Dur ≤ 96', '', '', '', '', '', '', '', '']
['Dur >96', '', '', '', '', '', '', '', '']
['Total\n(Any Duration)', '', '', '', '', '', '', '', '']
['Percent', '', '', '', '', '', '', '', '']

Extracted Table Text from Page:
aily Dose and Duration of Exposure Intravenous
Mean Daily Dose (mg)
20 < Dose
≤ 30mg
30 < Dose
≤ 50mg
50mg < Dose
Total
(Any Dose)
mum dose, or for dose of longest exposure. The same table c
asis of age groupings, sex, ethnic factors, comorbid conditi
concentration if such data are available.


--------------------------------------------------

Extracted Table from Page 165:
['', 'Treatment Groups', None, None]
[None, 'Test Product\nN =', 'Placebo\nN =', 'Active Control\nN =']
['Age (years)\nMean ± SD Range\nGroups\n<18\n18 - 40\n40 - 64\n65 - 75\n>75', '50 ± 15\n20-85\nN (%)\nN (%)\nN (%)\nN (%)\nN (%)', 'N (%)\nN (%)\nN (%)\nN (%)\nN (%)', 'N (%)\nN (%)\nN (%)\nN (%)\nN (%)']
['Sex\nFemale\nMale', 'N (%)\nN (%)', 'N (%)\nN (%)', 'N (%)\nN (%)']
['Race\nAsian\nBlack\nCaucasian\nOther', 'N (%)\nN (%)\nN (%)\nN (%)', 'N (%)\nN (%)\nN (%)\nN (%)', 'N (%)\nN (%)\nN (%)\nN (%)']
['Other Factors', '', '', '']

Extracted Table Text from Page:


--------------------------------------------------

Extracted Table from Page 166:
['body System / Adverse Event', 'Test Drug', None, None, 'Placebo', 'Active\nControl 1', 'Active Control 2', None]
['', 'All doses\nn = 1685', '10 mg\nn = 968', '20 mg\nn = 717', 'n = 425', '20 mg\nn = 653', '50 mg\nn = 334', '100 mg\nn = 546']
['Body as a whole', '', '', '', '', '', '', '']
['Dizziness', '19 (1%)', '7 (1%)', '12 (2%)', '6 (1%)', '23 (4%)', '1 (<1%)', '3 (1%)']
['Etc.', '', '', '', '', '', '', '']
['Cardiovascular', '', '', '', '', '', '', '']
['Postural Hypotension', '15 (1%)', '10 (1%)', '5 (1%)', '2 (<1%)', '7 (1%)', '6 (2%)', '12 (2%)']
['Etc.', '', '', '', '', '', '', '']
['Gastrointestinal', '', '', '', '', '', '', '']
['Constipation', '', '', '', '', '', '', '']

Extracted Table Text from Page:
ctive Controlled Trial Database
Placebo
Active 
Control 1
Active Control 2
n = 425
20 mg
n = 653
50 mg
n = 334
100 mg
n = 546
6 (1%)
23 (4%)
1 (<1%)
3 (1%)
2 (<1%)
7 (1%)
6 (2%)
12 (2%)


--------------------------------------------------

Extracted Table from Page 167:
['', 'Reported incidence by Treatment Groups', None, None, None, None, None, None, None]
['body System / Adverse Event', 'Study 95-0403', None, None, 'Study 96-0011', None, 'Study 97-0007', None, 'Study 98-0102s']
['', 'Drug x\n60 mg bid\nN =104', 'Drug x\n30 mg bid\nN =102', 'Placebo\nN = 100', 'Drug x\n60 mg bid\nN = 500', 'Placebo\nN=495', 'Drug x\n60 mg bid\nN=200', 'Drug y\n100 mg qd\nN=200', 'Drug x\n60 mg bid\nN=800']
['Body as a whole', '', '', '', '', '', '', '', '']
['Dizziness', 'N (%)', 'N (%)', 'N (%)', 'N (%)', 'N (%)', 'N (%)', 'N (%)', 'N (%)']
['Etc.', 'N (%)', 'N (%)', 'N (%)', 'N (%)', 'N (%)', 'N (%)', 'N (%)', 'N (%)']
['Cardiovascular', '', '', '', '', '', '', '', '']
['Postural Hypotension', '', '', '', '', '', '', '', '']
['Etc.', '', '', '', '', '', '', '', '']
['Gastrointestinal', '', '', '', '', '', '', '', '']
['Constipation', '', '', '', '', '', '', '', '']

Extracted Table Text from Page:
ence by Treatment Groups
dy 96-0011
Study 97-0007
x
id
0
Placebo
N=495
Drug x
60 mg bid
N=200
Drug y
100 mg qd
N=200
N (%)
N (%)
N (%)
N (%)
N (%)
N (%)


--------------------------------------------------

Extracted Table from Page 168:
['Studies', None, 'Total Withdrawal', None, None, None, 'Reason for Withdrawal', None, None, 'Number\nwithout post-\nwithdrawal\nefficacy data']
['', '', 'Total', 'Male/\nfemale', 'Age\n> 65', 'Race (identify\ngroupings) / / /', 'Adverse\nEvents\nN (%)', 'Lack of\nEfficacy\nN (%)', 'Other\nN (%)', 'N (%)']
['Study', 'Drug X', 'N (%)', 'N (%) /\nN (%)', 'N (%)', 'N (%) / N (%) /\nN (%)', '', '', '', '']
['XXX', 'Placebo', '', '', '', '', '', '', '', '']
['Study', 'Drug X', '', '', '', '', '', '', '', '']
['AAA', 'Comparator A', '', '', '', '', '', '', '', '']
['Study', 'Drug X', '', '', '', '', '', '', '', '']
['BBB', 'Comparator B', '', '', '', '', '', '', '', '']
['Study', 'Drug X', '', '', '', '', '', '', '', '']
['CCC', 'Comparator C', '', '', '', '', '', '', '', '']
['All Trials', '', '', '', '', '', '', '', '', '']

Extracted Table Text from Page:
ntrolled Trials
Reason for Withdrawal
Number 
without pos
withdrawa
efficacy da
ce (identify 
upings) / / /
Adverse
Events
N 
(%)
Lack of
Efficacy
N 
(%)
Other
N 
(%)
N 
(
%) / N (%) /
%)


--------------------------------------------------

Extracted Table from Page 169:
['Trial /\nSource1', 'Center', 'Patient\nID', 'Age\n(yrs)', 'Sex', 'Dose\n(mg)', 'Duration\nof\nexposure\n(Days)', 'Diagnosis', 'Cause\nof\nDeath', 'Other\nmedications', 'Other\nmedical\nconditions', 'Location of\nnarrative\ndescription']
['', '', '', '', '', '', '', '', '', '', '', '']
['', '', '', '', '', '', '', '', '', '', '', '']
['', '', '', '', '', '', '', '', '', '', '', '']

Extracted Table Text from Page:
her 
dical 
itions
Location of 
narrative 
description
rce, e.g., postmarking
sure or within a period
et during exposure or


--------------------------------------------------

Extracted Table from Page 171:
['Type of\nStudy', 'Study\nIdentifier', 'Location\nof Study\nReport', 'Objective(s)\nof the Study', 'Study Design\nand Type of\nControl', 'Test Product(s);\nDosage\nRegimen;\nRoute of\nAdministration', 'Number of\nSubjects', 'Healthy\nSubjects or\nDiagnosis of\nPatients', 'Duration of\nTreatment', 'Study Status;\nType of Report']
['BA', '001', 'Vol 3, Sec.\n1.1, p. 183', 'Absolute BA\nIV vs Tablet', 'Cross-over', 'Tablet, 50mg\nsingle dose, oral,\n10 mg IV', '20', 'Healthy\nSubjects', 'Single dose', 'Complete;\nAbbreviated']
['BE', '002', 'Vol 4, Sec.\n1.2, p. 254', 'Compare\nclinical study\nand to-be-\nmarketed\nformulation', 'Cross-over', 'Two tablet\nformulations, 50\nmg, oral', '32', 'Healthy\nSubjects', 'Single dose', 'Complete;\nAbbreviated']
['PK', '1010', 'Vol 6, Sec.\n3.3, p. 29', 'Define PK', 'Cross-over', 'Tablet, 50mg\nsingle dose, oral', '50', 'Renal\nInsufficiency', 'Single dose', 'Complete; Full']
['PD', '020', 'Vol 6, Sec.\n4.2, p. 147', 'Bridging\nstudy\nbetween\nregions', 'Randomised\nplacebo-\ncontrolled', 'Tablet, 50mg,\nmultiple dose,\noral, every 8 hrs', '24 (12 drug,\n12 placebo)', 'Patients\nwith primary\nhypertension', '2 weeks', 'Ongoing; Interim']
['Efficacy', '035', 'Vol 10, Sec.\n5.1, p. 1286', 'Long term;\nEfficacy\n& Safety;\nPopulation\nPK analysis', 'Randomised\nactive-\ncontrolled', 'Tablet, 50mg,\noral, every 8 hrs', '300 (152\ntest drug,\n148 active\ncontrol)', 'Patients\nwith primary\nhypertension', '48 weeks', 'Complete; Full']

Extracted Table Text from Page:
Design 
ype of 
ol
Test Product(s); 
Dosage 
Regimen;
Route of
Administration
Number of
Subjects
Healthy 
Subjects or 
Diagnosis of 
Patients
Duration of
Treatment
Study 
Type o
-over
Tablet, 50mg 
single dose, oral,
10 mg IV
20
Healthy
Subjects
Single dose
Compl
Abbrev
-over
Two tablet 
formulations, 50 
mg, oral
32
Healthy
Subjects
Single dose
Compl
Abbrev
-over
Tablet, 50mg 
single dose, oral
50
Renal
Insufficiency
Single dose
Compl
omised 
o- 
lled
Tablet, 50mg, 
multiple dose, 
oral, every 8 hrs
24 (12 drug,
12 placebo)
Patients 
with primary 
hypertension
2 weeks
Ongoin
omised 
- 
lled
Tablet, 50mg, 
oral, every 8 hrs
300 (152 
test drug,
148 active 
control)
Patients 
with primary 
hypertension
48 weeks
Compl


--------------------------------------------------

Extracted Table from Page 183:
['Type of\nStudy', 'Study\nIdentifier', 'Location\nof Study\nReport', 'Objective(s) of\nthe Study', 'Study\nDesign and\nType of\nControl', 'Test Product(s);\nDosage Regimen;\nRoute of\nAdministration', 'Number\nof\nSubjects', 'Healthy\nSubjects or\nDiagnosis\nof Patients', 'Duration\nof\nTreatment', 'Study\nStatus;\nType of\nReport']
['BA', '001', 'Vol 3,\nSec. 1.1,\np. 183', 'Absolute BA IV\nvs Tablet', 'Cross-over', 'Tablet, 50mg single\ndose, oral,\n10 mg IV', '20', 'Healthy\nSubjects', 'Single\ndose', 'Complete;\nAbbreviated']
['BE', '002', 'Vol 4,\nSec. 1.2,\np. 254', 'Compare clinical\nstudy and to-\nbe- marketed\nformulation', 'Cross-over', 'Two tablet\nformulations, 50\nmg, oral', '32', 'Healthy\nSubjects', 'Single\ndose', 'Complete;\nAbbreviated']
['PK', '1010', 'Vol 6,\nSec. 3.3,\np. 29', 'Define PK', 'Cross-over', 'Tablet, 50mg single\ndose, oral', '50', 'Renal\nInsufficiency', 'Single\ndose', 'Complete;\nFull']
['PD', '020', 'Vol 6,\nSec. 4.2,\np. 147', 'Bridging study\nbetween regions', 'Randomised\nplacebo-\ncontrolled', 'Tablet, 50mg,\nmultiple dose, oral,\nevery 8 hrs', '24 (12\ndrug, 12\nplacebo)', 'Patients with\nprimary\nhypertension', '2 weeks', 'Ongoing;\nInterim']
['Efficacy', '035', 'Vol 10,\nSec. 5.1,\np. 1286', 'Long term;\nEfficacy & Safety;\nPopulation PK\nanalysis', 'Randomised\nactive-\ncontrolled', 'Tablet, 50mg,\noral, every 8 hrs', '300 (152\ntest drug,\n148\nactive\ncontrol)', 'Patients\nwith primary\nhypertension', '48 weeks', 'Complete;\nFull']

Extracted Table Text from Page:
Test Product(s); 
Dosage Regimen; 
Route of 
Administration
Number 
of 
Subjects
Healthy 
Subjects or 
Diagnosis
of Patients
Duration 
of 
Treatment
Study
Status
Type 
Repo
Tablet, 50mg single 
dose, oral,
10 mg IV
20
Healthy
Subjects
Single 
dose
Comp
Abbre
Two tablet 
formulations, 50 
mg, oral
32
Healthy
Subjects
Single 
dose
Comp
Abbre
Tablet, 50mg single 
dose, oral
50
Renal 
Insufficiency
Single 
dose
Comp
Full
Tablet, 50mg, 
multiple dose, oral, 
every 8 hrs
24 (12 
drug, 12 
placebo)
Patients with 
primary
hypertension
2 weeks
Ongoi
Interim
Tablet, 50mg,
oral, every 8 hrs
300 (152
test drug,
148 
active 
control)
Patients
with primary 
hypertension
48 weeks
Comp
Full


--------------------------------------------------

Extracted Table from Page 188:
['Part IV : Clinical Document', 'NCE', 'bIOTECH', 'MaV', None, None, 'MiV', 'GP']
[None, None, None, 'RT', 'ST/P', 'IND', None, None]
['Section A. Table of Contents', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '-', '-']
['Section b. Clinical Overview\n1. Product Development Rationale\n2. Overview of Biopharmaceutics\n3. Overview of Clinical Pharmacology\n4. Overview of Efficacy\n5. Overview of Safety\n6. Benefits and Risks Conclusions', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '-', '-']
['Section C. Clinical Summary\n1. Summary of biopharmaceutic Studies and\nAssociated Analytical Method\n1.1 Background and Overview\n1.2 Summary of Results of Individual Studies\n1.3 Comparison and Analyses of Results Across\nStudies\nAppendix 1', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '-', '-']

Extracted Table Text from Page:




-


--------------------------------------------------

Extracted Table from Page 189:
['Part IV : Clinical Document', 'NCE', 'bIOTECH', 'MaV', None, None, 'MiV', 'GP']
[None, None, None, 'RT', 'ST/P', 'IND', None, None]
['Section C. Clinical Summary (Cont.)\n2. Summary of Clinical Pharmacology Studies\n2.1 Background and Overview\n2.2 Summary of Results of Individual Studies\n2.3 Comparison and Analyses of Results Across\nStudies\n2.4 Special Studies\nAppendix 2\n3. Summary of Clinical Efficacy\n3.1 Background and Overview of Clinical\nEfficacy\n3.2 Summary of Results of Individual Studies\n3.3 Comparison and Analyses of Results Across\nStudies\n3.4 Analysis of Clinical Information Relevant to\nDosing Recommendations\n3.5 Persistence of Efficacy and/or Tolerance\nEffects\nAppendix 3', '', '', '', '', '', '', '']

Extracted Table Text from Page:


--------------------------------------------------

Extracted Table from Page 190:
['Part IV : Clinical Document', 'NCE', 'bIOTECH', 'MaV', None, None, 'MiV', 'GP']
[None, None, None, 'RT', 'ST/P', 'IND', None, None]
['Section C. Clinical Summary (Cont.)\n4. Summary of Clinical Safety\n4.1 Exposure to the Drug\n4.2 Adverse Events\n4.3 Clinical Laboratory Evaluations\n4.4 Vital Signs, Physical Findings, and Other\nObservations Related to Safety\n4.5 Safety in Special Groups and Situations\n4.6 Post-marketing Data\nAppendix 4\n5.Synopses of Individual Studies', '', '', '', '', '', '', '']
['Section D. Tabular Listing of All Clinical Studies', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '-', '-']

Extracted Table Text from Page:




-
-


--------------------------------------------------

Extracted Table from Page 191:
['Part IV : Clinical Document', 'NCE', 'bIOTECH', 'MaV', None, None, 'MiV', 'GP']
[None, None, None, 'RT', 'ST/P', 'IND', None, None]
['Section E. Clinical Study Reports (if applicable)\n1. Reports of biopharmaceutic Studies\n1.1 BA Study Reports\n1.2 Comparative BA or BE Study Reports\n1.3 In vitro-In vivo Correlation Study Reports\n1.4 Reports of Bioanalytical and Analytical\nMethods for Human Studies\n2. Reports of Studies Pertinent to\nPharmacokinetics using Human biomaterials\n2.1 Plasma Protein Binding Study Reports\n2.2 Reports of Hepatic Metabolism and Drug\nInteraction Studies\n2.3 Reports of Studies Using Other Human\nBiomaterials', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '-', '-']

Extracted Table Text from Page:


--------------------------------------------------

Extracted Table from Page 192:
['Part IV : Clinical Document', 'NCE', 'bIOTECH', 'MaV', None, None, 'MiV', 'GP']
[None, None, None, 'RT', 'ST/P', 'IND', None, None]
['Section E. Clinical Study Reports (if applicable)\n3. Reports of Human Pharmacokinetic (PK)\nStudies\n3.1 Heatthy Subiect PK and Initial Tolerability\nStudy Reports\n3.2 Patient PK and Initial Tolerability Study\nReports\n3.3 Population PK Study Reports\n4. Reports of Human Pharmacodynamic (PD)\nStudies\n4.1 Healthy Subject PD and PK/PD Study\nReports\n4.2 Patient PD and PK/PD Study Reports', '', '', '', '', '', '', '']

Extracted Table Text from Page:


--------------------------------------------------

Extracted Table from Page 193:
['Part IV : Clinical Document', 'NCE', 'bIOTECH', 'MaV', None, None, 'MiV', 'GP']
[None, None, None, 'RT', 'ST/P', 'IND', None, None]
['Section E. Clinical Study Reports (if applicable)\n5. Reports of Efficacy and Safety Studies\n5.1 Study Reports of Controlled Clinical Studies\nPertinent to the Claimed Indication\n5.2 Study Reports of Uncontrolled Clinical\nStudies\n5.3 Reports of Analyses of Data from More Than\nOne Study, Including Any Formal Integrated\nAnalyses, Meta-analyses, and Bridging\nAnalyses\n5.4 Other Clinical Study Reports\n6. Reports of Post-Marketing Experience\n7. Case Report forms and Individual Patient\nListing', '', '', '', '', '', '', '']
['Section f. List of Key Literature References', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '\uf0fc', '-', '-']

Extracted Table Text from Page:





-
-
 
 


--------------------------------------------------

Extracted Table from Page 194:
[None, None, 'ASEAN\nACTD\nCOMMON\nTECHNICAL\nDOSSIER\nties', None, None]
[None, 'ASEAN: A Community of Opportunities\nASEAN\n@ASEAN\nASEAN\nwww.asean.org', 'ties', '', 'ASEAN\nACTD\nCOMMON\nTECHNICAL\nDOSSIER']
[None, None, None, '', 'one vision\none identity\none community']
['B ACTD', 'B ACTD', None, None, None]

Extracted Table Text from Page:


--------------------------------------------------
